ArticleAntimicrobial agents and chemotherapy2009
Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.
Article in Antimicrobial agents and chemotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed.
- Antifungal Susceptibility Testing Experience in the Management of Culture-Positive Mucormycosis: Observation from a Large Healthcare System.Journal of fungi (Basel, Switzerland) · 2026Article
- Rapid Diagnosis of Mucor and Aspergillus Co-Infection by Direct Microscopic Examination: A Case Report and Literature Review.Infection and drug resistance · 2026Article
- Two decades of mucormycosis: molecular epidemiology and antifungal susceptibility trends in Türkiye.Frontiers in cellular and infection microbiology · 2026Article
- Monoclonal Antibodies Can Aid in the Culture-Based Detection and Differentiation ofAntibodies (Basel, Switzerland) · 2025Article
- SIADH secondary to rhino-orbito-cerebral mucormycosis: A case report.Clinical case reports · 2024Article
- Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.Frontiers in microbiology · 2024Review
- In vitro combination with doxycycline plus antifungals against clinical Mucorales pathogens.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- COVID-19 Associated Rhino-Orbital-Cerebral Mucormycosis: Clinical Features, Antifungal Susceptibility, Management and Outcome in a Tertiary Hospital in Iran.Mycopathologia · 2023Article
- Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- A peek behind the curtain in the diagnosis and management of COVID‑19‑Associated Mucormycosis (CAM).The Journal of the Egyptian Public Health Association · 2023Review
- Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19.Environmental science and pollution research international · 2023Review
- A 40-Year-Old Woman With COVID-19 and Bilateral Vision Loss.The Neurohospitalist · 2022Article
- COVID-19 Associated Mucormycosis: A Systematic Review from Diagnostic Challenges to Management.Diseases (Basel, Switzerland) · 2021Review
- First reported case of Gilbertella persicaria in human stool: outcome of a community study from Segamat, Johor, Malaysia.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
- A Revised Species Concept for OpportunisticAntimicrobial agents and chemotherapy · 2019Article
- In Vitro Activity of Amphotericin B in Combination with Statins against Clinical and EnvironmentalIranian journal of public health · 2019Article
- Molecular Identification and Susceptibility Testing of Molds Isolated in a Prospective Surveillance of Triazole Resistance in Spain (FILPOP2 Study).Antimicrobial agents and chemotherapy · 2018Article
- Sterol Composition of Clinically Relevant Mucorales and Changes Resulting from Posaconazole Treatment.Molecules (Basel, Switzerland) · 2018Article
- Challenges in the diagnosis and treatment of mucormycosis.Medical mycology · 2018Review
- Rare fungal infectious agents: a lurking enemy.F1000Research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The antifungal susceptibility profiles of 77 clinical strains of Mucorales species, identified by internal transcribed spacer sequencing, were analyzed. MICs obtained at 24 and 48 h were compared. Amphotericin B was the most active agent against all isolates, except for Cunninghamella and Apophysomyces isolates. Posaconazole also showed good activity for all species but Cunninghamella bertholletiae. Voriconazole had no activity against any of the fungi tested. Terbinafine showed good activity, except for Rhizopus oryzae, Mucor circinelloides, and Rhizomucor variabilis isolates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.